Apigenin
Sleep & Recovery · Flavonoid / GABA-A modulator
Tier C+
Bottom line
Read Off Label grades Apigenin as C+ (5.5/10) based on weak evidence, low-moderate benefit magnitude, and a low-risk safety profile.
Huberman-driven popularization (magnesium threonate + apigenin + theanine).
Studied, labeled, or reported-use context: 50 mg before bed (popularized dose from Huberman sleep stack) — OTC; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
A CD38 inhibitor, which gives it a specific and interesting mechanism — CD38 consumes NAD+ and rises with age, so inhibiting it is a mechanistically distinct route to the same target the NAD+ precursors chase, potentially a more efficient one.
Why it may not get there
The CD38 work is preclinical and the concentrations used in vitro are far above what oral apigenin achieves; bioavailability is poor. Human data are essentially limited to sleep and anxiolytic use at chamomile-derived doses, which is a different claim entirely. No human study has shown a change in NAD+ from apigenin.
What would change this A human study measuring NAD+ after apigenin dosing.
What the evidence says
Huberman-driven popularization (magnesium threonate + apigenin + theanine). Chamomile tea is the traditional dietary source. Mechanism plausible; dedicated trials in humans minimal. Small studies report sedative or sleep-related effects; comparative sleep-outcome evidence is limited.
Mechanism
Flavonoid from chamomile, parsley, celery; GABA-A receptor binding (benzodiazepine site partial agonist); mild anxiolytic/sedative; aromatase inhibition (modest estradiol reduction)
Studied, labeled, or reported dose & route
50 mg before bed (popularized dose from Huberman sleep stack)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Apigenin's effects?
- Read Off Label rates the evidence for Apigenin as Weak and the benefit magnitude as low-moderate, producing an overall grade of C+ (5.5/10). Huberman-driven popularization (magnesium threonate + apigenin + theanine).
- What safety findings are reported for Apigenin?
- Apigenin has a low risk profile in the database. Low (theoretical concerns with anticoagulants; aromatase inhibition not relevant at typical supplement doses) Legal status: OTC.
- What doses or routes are reported for Apigenin?
- 50 mg before bed (popularized dose from Huberman sleep stack) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Apigenin work?
- Flavonoid from chamomile, parsley, celery; GABA-A receptor binding (benzodiazepine site partial agonist); mild anxiolytic/sedative; aromatase inhibition (modest estradiol reduction)
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.